Neurophysiological Characteristics in Type II and Type III 5q Spinal Muscular Atrophy Patients: Impact of Nusinersen Treatment

References

• Bürglen L, Lefebvre S, Clermont O, et al. Structure and organization of the human survival motor neurone (SMN) gene. Genomics. 1996;32(3):479–482. doi:10.1006/geno.1996.0147
   PubMed Web of Science ®Google Scholar
• Prior TW, Bayrak-Toydemir P, Lynnes TC, et al. Characterization of reference materials for spinal muscular atrophy genetic testing: a genetic testing reference materials coordination program collaborative project. J Mol Diagn. 2021;23(1):103–110. doi:10.1016/j.jmoldx.2020.10.011
   PubMed Web of Science ®Google Scholar
• Milligan JN, Blasco-Pérez L, Costa-Roger M, et al. Recommendations for interpreting and reporting silent carrier and disease-modifying variants in SMA testing workflows. Genes. 2022;13(9):1657. doi:10.3390/genes13091657
   PubMed Web of Science ®Google Scholar
• Jędrzejowska M, Kostera-Pruszczyk A. Spinal muscular atrophy—new therapies, new challenges. Neurologia i Neurochirurgia Polska. 2020;54(1):8–13. doi:10.5603/PJNNS.a2019.0068
   PubMed Web of Science ®Google Scholar
• Wojcik MH, Schwartz TS, Thiele KE, et al. Infant mortality: the contribution of genetic disorders. J Perinatol. 2019;39(12):1611–1619. doi:10.1038/s41372-019-0451-5
   PubMed Web of Science ®Google Scholar
• Jangi M, Fleet C, Cullen P, et al. SMN deficiency in severe models of spinal muscular atrophy causes widespread intron retention and DNA damage. Proc Natl Acad Sci. 2017;114(12):E2347–E2356. doi:10.1073/pnas.1613181114
   PubMed Web of Science ®Google Scholar
• Gavriilaki M, Moschou M, Papaliagkas V, et al. Biomarkers of disease progression in adolescents and adults with 5q spinal muscular atrophy: a systematic review and meta-analysis. Neuromuscul Disord. 2022;32(3):185–194. doi:10.1016/j.nmd.2021.12.005
   PubMed Web of Science ®Google Scholar
• Arnold WD, Burghes AH. Spinal muscular atrophy: development and implementation of potential treatments. Ann Neurol. 2013;74(3):348–362. doi:10.1002/ana.23995
   PubMed Web of Science ®Google Scholar
• Garg N, Howells J, Yiannikas C, et al. Motor unit remodelling in multifocal motor neuropathy: the importance of axonal loss. Clin Neurophysiol. 2017;128(10):2022–2028. doi:10.1016/j.clinph.2017.07.414
   PubMed Web of Science ®Google Scholar
• Yonekawa T, Komaki H, Saito Y, et al. Peripheral nerve abnormalities in pediatric patients with spinal muscular atrophy. Brain Dev. 2013;35(2):165–171. doi:10.1016/j.braindev.2012.03.009
   PubMed Web of Science ®Google Scholar
• Hoy SM. Nusinersen: first global approval. Drugs. 2017;77(4):473–479. doi:10.1007/s40265-017-0711-7
   PubMed Web of Science ®Google Scholar
• Pechmann A, Behrens M, Dörnbrack K, et al. Improvements in walking distance during nusinersen treatment–a prospective 3-year SMArtCARE registry study. J Neuromu Dis. 2023;10(1):29–40. doi:10.3233/JND-221600
   PubMedGoogle Scholar
• Klotz J, Tesi Rocha C, Dunaway Young S, et al. Advances in the therapy of spinal muscular atrophy. J Pediatr. 2021;236:13–20.e11. doi:10.1016/j.jpeds.2021.06.033
   PubMed Web of Science ®Google Scholar
• Łusakowska A, Wójcik A, Frączek A, et al. Long-term nusinersen treatment across a wide spectrum of spinal muscular atrophy severity: a real-world experience. Orphanet J Rare Diseases. 2023;18(1):230. doi:10.1186/s13023-023-02769-4
   PubMed Web of Science ®Google Scholar
• Michelson D, Ciafaloni E, Ashwal S, et al. Evidence in focus: nusinersen use in spinal muscular atrophy: report of the Guideline development, dissemination, and implementation subcommittee of the American Academy of neurology. Neurology. 2018;91(20):923–933. doi:10.1212/WNL.0000000000006502
   PubMed Web of Science ®Google Scholar
• Gavriilaki M, Moschou M, Papaliagkas V, et al. Nusinersen in adults with 5q spinal muscular atrophy: a systematic review and meta-analysis. Neurotherapeutics. 2022;19(2):464–475. doi:10.1007/s13311-022-01200-3
   PubMed Web of Science ®Google Scholar
• Gavriilaki M, Papaliagkas V, Stamperna A, et al. Biomarkers of therapeutic efficacy in adolescents and adults with 5q spinal muscular atrophy: a systematic review. Acta Neurologica Belgica. 2023;123(5):1735–1745. doi:10.1007/s13760-022-02028-6
   PubMed Web of Science ®Google Scholar
• Axente M, Mirea A, Sporea C, et al. Clinical and electrophysiological changes in pediatric spinal muscular atrophy after 2 years of nusinersen treatment. Pharmaceutics. 2022;14(10):2074. doi:10.3390/pharmaceutics14102074
   PubMed Web of Science ®Google Scholar
• Kariyawasam D, D’Silva A, Howells J, et al. Motor unit changes in children with symptomatic spinal muscular atrophy treated with nusinersen. J Neurol Neurosurg. 2021;92(1):78–85. doi:10.1136/jnnp-2020-324254
   Web of Science ®Google Scholar
• Coratti G, Pera MC, Lucibello S, et al. Age and baseline values predict 12 and 24-month functional changes in type 2 SMA. Neuromuscul Disord. 2020;30(9):756–764. doi:10.1016/j.nmd.2020.07.005
   PubMed Web of Science ®Google Scholar
• Polat I, Can Yilmaz G, Dedeoglu O. Vitamin D and nerve conduction in pediatric type-1 diabetes mellitus. Brain Dev. 2022;44(5):336–342. doi:10.1016/j.braindev.2022.01.001
   PubMed Web of Science ®Google Scholar
• Szabó L, Gergely A, Jakus R, et al. Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: real world data from Hungarian patients. Eur J Paediatr Neurol. 2020;27:37–42. doi:10.1016/j.ejpn.2020.05.002
   PubMed Web of Science ®Google Scholar
• Salort-Campana E, Quijano-Roy S. Clinical features of spinal muscular atrophy (SMA) type 3 (Kugelberg-Welander disease). Arch Pediatr. 2020;27(7s):7s23–27s28. doi:10.1016/S0929-693X(20)30273-6
   PubMedGoogle Scholar
• Arnold WD, Porensky PN, McGovern VL, et al. Electrophysiological Biomarkers in Spinal Muscular Atrophy: preclinical Proof of Concept. Ann Clin Transl Neurol. 2014;1(1):34–44. doi:10.1002/acn3.23
   PubMed Web of Science ®Google Scholar
• Finkel RS. Electrophysiological and motor function scale association in a pre-symptomatic infant with spinal muscular atrophy type I. Neuromuscul Disord. 2013;23(2):112–115. doi:10.1016/j.nmd.2012.09.006
   PubMed Web of Science ®Google Scholar
• Weng WC, Hsu YK, Chang FM, et al. CMAP changes upon symptom onset and during treatment in spinal muscular atrophy patients: lessons learned from newborn screening. Genet Med. 2021;23(2):415–420. doi:10.1038/s41436-020-00987-w
   PubMed Web of Science ®Google Scholar
• Boulay C, Delmont E, Audic F, et al. Motor unit number index: a potential electrophysiological biomarker for pediatric spinal muscular atrophy. Muscle Nerve. 2021;64(4):445–453. doi:10.1002/mus.27372
   PubMed Web of Science ®Google Scholar
• Barrois R, Barnerias C, Deladrière E, et al. A new score combining compound muscle action potential (CMAP) amplitudes and motor score is predictive of motor outcome after AVXS-101 (Onasemnogene Abeparvovec) SMA therapy. Neuromuscul Disord. 2023;33(4):309–314. doi:10.1016/j.nmd.2023.02.004
   PubMed Web of Science ®Google Scholar
• Messina S, Sframeli M. New treatments in spinal muscular atrophy: positive results and new challenges. J Clin Med. 2020;9(7):2222. doi:10.3390/jcm9072222
   PubMed Web of Science ®Google Scholar
• Servais L, Bloespflug-Tanguy O, Darras B, et al. Sma – therapy. Neuromuscul Disord. 2020;1:30.
   Google Scholar
• Kariyawasam D, D’Silva A, Howells J, et al. Motor unit changes in children with symptomatic spinal muscular atrophy treated with nusinersen. J Neurol Neurosurg Psychiatry. 2020;92(1):78–85.
   PubMed Web of Science ®Google Scholar
• Coratti G, Lucibello S, Pera MC, et al. Gain and loss of abilities in type II SMA: a 12-month natural history study. Neuromuscul Disord. 2020;30(9):765–771. doi:10.1016/j.nmd.2020.07.004
   PubMed Web of Science ®Google Scholar
• Elsheikh B, Severyn S, Zhao S, et al. Safety, tolerability, and effect of nusinersen in non-ambulatory adults with spinal muscular atrophy. Front Neurol. 2021;12:650532. doi:10.3389/fneur.2021.650532
   PubMed Web of Science ®Google Scholar
• Arnold WD, Severyn S, Zhao S, et al. Persistent neuromuscular junction transmission defects in adults with spinal muscular atrophy treated with nusinersen. BMJ Neu Open. 2021;3(2):e000164. doi:10.1136/bmjno-2021-000164
   PubMedGoogle Scholar
• Coratti G, Pane M, Lucibello S, et al. Age related treatment effect in type II spinal muscular atrophy pediatric patients treated with nusinersen. Neuromuscul Disord. 2021;31(7):596–602. doi:10.1016/j.nmd.2021.03.012
   PubMed Web of Science ®Google Scholar
• Osredkar D, Jílková M, Butenko T, et al. Children and young adults with spinal muscular atrophy treated with nusinersen. Eur J Paediatr Neurol. 2021;30:1–8. doi:10.1016/j.ejpn.2020.11.004
   PubMed Web of Science ®Google Scholar